- Home
- LAB vs ZBIO Comparison
LAB vs ZBIO Comparison
Compare LAB & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- ZBIO
- Stock Information
- Founded
- LAB 1999
- ZBIO 2019
- Country
- LAB United States
- ZBIO United States
- Employees
- LAB N/A
- ZBIO N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- ZBIO
- Sector
- LAB Industrials
- ZBIO
- Exchange
- LAB Nasdaq
- ZBIO NYSE
- Market Cap
- LAB 462.4M
- ZBIO 389.2M
- IPO Year
- LAB 2011
- ZBIO 2024
- Fundamental
- Price
- LAB $1.24
- ZBIO $12.15
- Analyst Decision
- LAB Buy
- ZBIO Strong Buy
- Analyst Count
- LAB 2
- ZBIO 7
- Target Price
- LAB $2.50
- ZBIO $32.29
- AVG Volume (30 Days)
- LAB 2.8M
- ZBIO 189.4K
- Earning Date
- LAB 07-30-2025
- ZBIO 08-16-2025
- Dividend Yield
- LAB N/A
- ZBIO N/A
- EPS Growth
- LAB N/A
- ZBIO N/A
- EPS
- LAB N/A
- ZBIO N/A
- Revenue
- LAB $169,687,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- LAB N/A
- ZBIO $165.20
- Revenue Next Year
- LAB $12.18
- ZBIO $63.75
- P/E Ratio
- LAB N/A
- ZBIO N/A
- Revenue Growth
- LAB 33.86
- ZBIO N/A
- 52 Week Low
- LAB $0.92
- ZBIO $5.83
- 52 Week High
- LAB $2.41
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- LAB 52.66
- ZBIO N/A
- Support Level
- LAB $1.27
- ZBIO N/A
- Resistance Level
- LAB $1.41
- ZBIO N/A
- Average True Range (ATR)
- LAB 0.08
- ZBIO 0.00
- MACD
- LAB -0.00
- ZBIO 0.00
- Stochastic Oscillator
- LAB 38.46
- ZBIO 0.00
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.